{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:33:03Z","timestamp":1790321583517,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.neuropharm.2019.05.025","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T20:58:56Z","timestamp":1558731536000},"page":"131-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"special_numbering":"C","title":["New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease"],"prefix":"10.1016","volume":"155","author":[{"given":"Irina","family":"Zueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6922-020X","authenticated-orcid":false,"given":"Sofya","family":"Lushchekina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav","family":"Semenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Mukhamedyarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Pashirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliy","family":"Babaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0293-2429","authenticated-orcid":false,"given":"Florian","family":"Nachon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leniz","family":"Nurullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Zakharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Ilyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Petrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.05.025_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0006-2952(02)01514-9","article-title":"\u03b2-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies","volume":"65","author":"Bartolini","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/brain\/awm276","article-title":"Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology","volume":"131","author":"Berson","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib4","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1021\/ct300400x","article-title":"Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone phi, psi and side-chain chi(1) and chi(2) dihedral angles","volume":"8","author":"Best","year":"2012","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089454","article-title":"Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease","volume":"9","author":"Bhattacharya","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib6","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pep.2007.04.013","article-title":"A combined approach to improving large-scale production of tobacco etch virus protease","volume":"55","author":"Blommel","year":"2007","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/brain\/99.3.459","article-title":"Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies","volume":"99","author":"Bowen","year":"1976","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib9","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.1523\/JNEUROSCI.1697-05.2005","article-title":"Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease","volume":"25","author":"Buttini","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib10","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1021\/ja804941z","article-title":"Aging of cholinesterases phosphylated by tabun proceeds through O-dealkylation","volume":"130","author":"Carletti","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib11","doi-asserted-by":"crossref","first-page":"11706","DOI":"10.1038\/s41598-017-09780-3","article-title":"Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease","volume":"7","author":"Cavedo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib12","doi-asserted-by":"crossref","first-page":"10282","DOI":"10.1021\/jm300871x","article-title":"Structures of human acetylcholinesterase in complex with pharmacologically important ligands","volume":"55","author":"Cheung","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biocel.2007.07.013","article-title":"Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease","volume":"40","author":"Crouch","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib14","first-page":"109","article-title":"Defining disease modifying therapy for Alzheimer's disease","volume":"4","author":"Cummings","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib15","doi-asserted-by":"crossref","first-page":"2320 e2315","DOI":"10.1016\/j.neurobiolaging.2010.04.028","article-title":"Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo","volume":"32","author":"Darreh-Shori","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-130845","article-title":"Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors","volume":"39","author":"Darreh-Shori","year":"2014","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3233\/JAD-2011-111088","article-title":"Apolipoprotein epsilon 4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease","volume":"28","author":"Darreh-Shori","year":"2012","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib18","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer's disease","volume":"308","author":"Davies","year":"1976","journal-title":"The Lancet"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib19","doi-asserted-by":"crossref","first-page":"10447","DOI":"10.1021\/bi0101392","article-title":"A structural motif of acetylcholinesterase that promotes amyloid \u03b2-peptide fibril formation","volume":"40","author":"De Ferrari","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nprot.2006.2","article-title":"T-maze alternation in the rodent","volume":"1","author":"Deacon","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.brainres.2009.09.097","article-title":"Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease","volume":"1303","author":"Dong","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib22","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/01.wnl.0000344650.95823.03","article-title":"Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial","volume":"72","author":"Doody","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib23","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jalz.2014.10.003","article-title":"Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease","volume":"11","author":"Dubois","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib24","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000113688","article-title":"Potent beta-amyloid modulators","volume":"5","author":"Garcia-Palomero","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1176\/appi.ajp.162.4.676","article-title":"Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?","volume":"162","author":"Hashimoto","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nm0198-097","article-title":"Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes","volume":"4","author":"Holcomb","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib29","first-page":"359","article-title":"Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments","volume":"1","author":"Inestrosa","year":"1996","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib30","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0896-6273(00)80108-7","article-title":"Acetylcholinesterase accelerates assembly of amyloid-\u03b2-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme","volume":"16","author":"Inestrosa","year":"1996","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1742-4658.2007.06238.x","article-title":"Amyloid-cholinesterase interactions. Implications for Alzheimer's disease","volume":"275","author":"Inestrosa","year":"2008","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112311","article-title":"Diverse effects of an acetylcholinesterase inhibitor, donepezil, on hippocampal neuronal death after pilocarpine-induced seizure","volume":"18","author":"Jeong","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"Xds","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib34","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1042\/BCJ20160084","article-title":"Slow-binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6-methyluracil: mechanism and possible advantages for myasthenia gravis treatment","volume":"473","author":"Kharlamova","year":"2016","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib35","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1073\/pnas.0811698106","article-title":"Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques","volume":"106","author":"Koffie","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib36","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1176\/appi.ajp.160.11.2003","article-title":"Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease","volume":"160","author":"Krishnan","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0969-2126(99)80040-9","article-title":"Structure of acetylcholinesterase complexed with E2020 (Aricept\u00ae): implications for the design of new anti-Alzheimer drugs","volume":"7","author":"Kryger","year":"1999","journal-title":"Structure"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib38","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3233\/JAD-142268","article-title":"Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value","volume":"44","author":"Lane","year":"2015","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/med.20248","article-title":"Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease","volume":"33","author":"Leon","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib40","first-page":"618","article-title":"Inhibition of BACE1 for therapeutic use in Alzheimer's disease","volume":"3","author":"Luo","year":"2010","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib41","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12668-016-0375-x","article-title":"Role of acetylcholinesterase in \u03b2-amyloid aggregation studied by accelerated molecular dynamics","volume":"7","author":"Lushchekina","year":"2016","journal-title":"BioNanoScience"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib42","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib43","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ajpath.2013.10.010","article-title":"alpha 7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles","volume":"184","author":"Medeiros","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib44","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/ana.410360506","article-title":"Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia","volume":"36","author":"Mesulam","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib45","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.bbadis.2016.01.013","article-title":"Role of P-glycoprotein in mediating rivastigmine effect on amyloid-beta brain load and related pathology in Alzheimer's disease mouse model","volume":"1862","author":"Mohamed","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2174\/092986706775527974","article-title":"Dimeric and hybrid anti-alzheimer drug candidates","volume":"13","author":"Munoz-Torrero","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nm.1912","article-title":"Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease","volume":"15","author":"Nagahara","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejphar.2012.12.023","article-title":"Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine","volume":"703","author":"Nagakura","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib49","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1126\/science.1411529","article-title":"Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors","volume":"258","author":"Nitsch","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(77)91780-9","article-title":"Necropsy evidence of central cholinergic deficits in senile dementia","volume":"309","author":"Perry","year":"1977","journal-title":"The Lancet"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib51","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuropharm.2017.12.034","article-title":"C-547, a 6-methyluracil derivative with long-lasting binding and rebinding on acetylcholinesterase: pharmacokinetic and pharmacodynamic studies","volume":"131","author":"Petrov","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib52","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41598-017-18307-9","article-title":"Specific inhibition of acetylcholinesterase as an approach to decrease muscarinic side effects during myasthenia gravis treatment","volume":"8","author":"Petrov","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib53","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1476-5381.2011.01211.x","article-title":"Different sensitivities of rat skeletal muscles and brain to novel anti-cholinesterase agents, alkylammonium derivatives of 6-methyluracil (ADEMS)","volume":"163","author":"Petrov","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib54","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib55","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000113711","article-title":"Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro","volume":"5","author":"Podoly","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib56","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer's disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib57","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0197-4580(02)00230-0","article-title":"Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex","volume":"24","author":"Rees","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/1567205054367847","article-title":"Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice","volume":"2","author":"Rees","year":"2005","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib59","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0002-9440(10)63774-1","article-title":"Acetylcholinesterase-a\u03b2 complexes are more toxic than A\u03b2 fibrils in rat Hippocampus","volume":"164","author":"Reyes","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib60","series-title":"Contemporary High Performance Computing: from Petascale toward Exascale","first-page":"283","article-title":"Lomonosov\": supercomputing at Moscow state university","author":"Sadovnichy","year":"2013"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib61","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/01.WNL.0000134664.80320.92","article-title":"Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial","volume":"63","author":"Salloway","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib62","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib63","doi-asserted-by":"crossref","first-page":"2318 e2331","DOI":"10.1016\/j.neurobiolaging.2010.04.005","article-title":"An MRI substudy of a donepezil clinical trial in mild cognitive impairment","volume":"32","author":"Schuff","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib64","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1039\/C4MD00225C","article-title":"Macrocyclic derivatives of 6-methyluracil as ligands of the peripheral anionic site of acetylcholinesterase","volume":"5","author":"Semenov","year":"2014","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib65","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/cmdc.201500334","article-title":"6-Methyluracil derivatives as bifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease","volume":"10","author":"Semenov","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib66","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuroscience.2007.04.011","article-title":"Beta-amyloid pathology in the entorhinal cortex of rats induces memory deficits: implications for Alzheimer's disease","volume":"147","author":"Sipos","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib67","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1248\/bpb.32.318","article-title":"Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation","volume":"32","author":"Takada-Takatori","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib68","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1124\/jpet.103.050104","article-title":"Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons","volume":"306","author":"Takada","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib69","doi-asserted-by":"crossref","first-page":"40180","DOI":"10.1074\/jbc.M110.142356","article-title":"Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors","volume":"285","author":"Takata","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hipo.450010102","article-title":"Entorhinal cortex pathology in Alzheimer's disease","volume":"1","author":"Van Hoesen","year":"1991","journal-title":"Hippocampus"},{"key":"10.1016\/j.neuropharm.2019.05.025_bib71","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1021\/jm401824w","article-title":"Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents","volume":"57","author":"Viayna","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib72","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000478741","article-title":"Lessons from anti-amyloid-beta immunotherapies in alzheimer disease: aiming at a moving target","volume":"17","author":"Wang","year":"2017","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib73","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000091790","article-title":"3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy","volume":"21","author":"Winblad","year":"2006","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib74","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3233\/JAD-2011-110551","article-title":"Quantifying the pathophysiological timeline of Alzheimer's disease","volume":"26","author":"Yang","year":"2011","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib75","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1523\/JNEUROSCI.2851-16.2017","article-title":"Regulation of synaptic amyloid-beta generation through BACE1 retrograde transport in a mouse model of Alzheimer's disease","volume":"37","author":"Ye","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.05.025_bib76","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0304-3940(01)01855-9","article-title":"Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen\u2013glucose deprivation","volume":"306","author":"Zhou","year":"2001","journal-title":"Neurosci. Lett."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818305197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818305197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:54:44Z","timestamp":1758437684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818305197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":76,"alternative-id":["S0028390818305197"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.05.025","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}